Search hospitals > Pennsylvania > Philadelphia
Pennsylvania Hospital
Claim this profilePhiladelphia, Pennsylvania 19107
Global Leader in Cancer
Global Leader in Ovarian Cancer
Conducts research for Peritoneal Cancer
Conducts research for Fallopian Tube Cancer
Conducts research for Adenocarcinoma
140 reported clinical trials
11 medical researchers
Summary
Pennsylvania Hospital is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Cancer, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Adenocarcinoma and other specialties. Pennsylvania Hospital is involved with conducting 140 clinical trials across 259 conditions. There are 11 research doctors associated with this hospital, such as Patricia A. Locantore-Ford, Ari Brooks, MD, Lisa Levine, MD, MSCE, and Gary M. Freedman.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Ovarian Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Patricia A. Locantore-FordPennsylvania Hospital8 years of reported clinical research
Studies Cancer
Studies Lymphoma
6 reported clinical trials
22 drugs studied
Ari Brooks, MDUniversity of Pennsylvania3 years of reported clinical research
Studies Nipple Sparing Mastectomy
Studies Breast Cancer
3 reported clinical trials
5 drugs studied
Lisa Levine, MD, MSCEPennsylvania Hospital1 year of reported clinical research
Studies Prolonged Pregnancy
Studies Cardiovascular Disease
3 reported clinical trials
3 drugs studied
Gary M. FreedmanAbramson Cancer Center of the University of Pennsylvania11 years of reported clinical research
Studies Breast Cancer
2 reported clinical trials
5 drugs studied
Clinical Trials running at Pennsylvania Hospital
Cancer
Anal Cancer
Anal Squamous Cell Carcinoma
Solid Tumors
Breast Cancer
Squamous Cell Carcinoma
Lymphoma
Tumors
Endometrial Cancer
Rectal Cancer
Nivolumab + Chemotherapy
for Anal Cancer
This trial is testing whether adding nivolumab to standard chemotherapy is more effective for patients with metastatic anal cancer. Nivolumab helps the immune system fight cancer, while chemotherapy kills or stops cancer cells from growing. Nivolumab has shown significant effectiveness in treating metastatic squamous cell carcinoma of the anal canal.
Recruiting2 awards Phase 321 criteria
Nivolumab + Ipilimumab
for Cancer
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory), or solid tumors that have spread from where it first started to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ipilimumab is an antibody that acts against a molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 controls a part of the immune system by shutting it down. Nivolumab is a type of antibody that is specific for human programmed cell death 1 (PD-1), a protein that is responsible for destruction of immune cells. Giving ipilimumab with nivolumab may work better in treating patients with HIV associated classical Hodgkin lymphoma or solid tumors compared to ipilimumab with nivolumab alone.
Recruiting1 award Phase 127 criteria
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Pennsylvania Hospital?
Pennsylvania Hospital is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Cancer, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Adenocarcinoma and other specialties. Pennsylvania Hospital is involved with conducting 140 clinical trials across 259 conditions. There are 11 research doctors associated with this hospital, such as Patricia A. Locantore-Ford, Ari Brooks, MD, Lisa Levine, MD, MSCE, and Gary M. Freedman.